Skip to main content

Evidence-Based Supplement Research

Evidence-Based Supplement Research

L-Arginine and Reduced Time to Crisis Resolution

Doses used in studies

mg/kg/day: 100 (median 100, IQR 100–100) — 1 study

Safety in these studies

hospital readmissionNo significant differenceSerious adverse eventRR 1.23, 95% CI [0.92, 1.65]
A non-significant 23% increase in hospital readmission risk was observed (RR 1.23, 95% CI [0.92, 1.65]).
from: Arginine therapy in sickle cell disease: A systematic review and meta-analysis of clinical

2 of 2 papers

Arginine therapy in sickle cell disease: A systematic review and meta-analysis of clinical outcomes.
- 2026-04
- Meta-Analysis · n = 830
- Clinical nutrition ESPEN 72
- - Favour M L Foncha
  - Joseph Y Bena Nnang
  - Samuel G J Fodop
  - Best C I Poudjoum
  - Dimitri S Tcheuko
  - Joel G K Mekontso
- PubMed: 41534622
- DOI: 10.1016/j.clnesp.2025.102898
5 Insights on
- Reduced Time to Crisis Resolution
- High evidence
- Clinical
no significant differences were observed for time to crisis resolution (MD -12.64 h, 95 % CI [-25.82, 0.54])
Effect
Neutral
Effect size
Small
Significant
No
The efficacy of oral L-arginine therapy for the treatment of vaso-occlusive pain episodes in children with sickle cell disease.
- 2025-08-27
- RCT · n = 20
- Pediatric hematology and oncology 42(6-7)
- - Aya Mohamed Abd Elglil
  - Mohamed Ramadan El-Shanshory
  - Hamed Mohamed Elsharkawy
  - Walaa Arafa Keshk
  - Nahed M Hablas
  - Lamia M Morad
- PubMed: 40862485
- DOI: 10.1080/08880018.2025.2549365
4 Insights on
- Reduced Time to Crisis Resolution
- High evidence
- Clinical
time to crisis resolution (p-value 0.011)
Effect
Beneficial
Effect size
Moderate
Significant
Yes
Dose
100 mg/kg/dose three times/day for 15 doses or until discharge